☰

Lisa Danae Johnson - Publications

Affiliations: 
2010 Microbiology, Immunology and Cancer Biology University of Minnesota, Twin Cities, Minneapolis, MN 
Tree Info Similar researchers PubMed Report error

20 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Yirsaw AW, Gillespie A, Briton E, Doerle A, Johnson L, Marston S, Telfer J, Baldwin CL. Goat γδ T cell subpopulations defined by WC1 expression, responses to pathogens and cytokine production. Developmental and Comparative Immunology. 103984. PMID 33352199 DOI: 10.1016/j.dci.2020.103984  0.361
2019 Uger R, Johnson L. Blockade of the CD47-SIRPα axis: a promising approach for cancer immunotherapy. Expert Opinion On Biological Therapy. 20: 5-8. PMID 31663384 DOI: 10.1080/14712598.2020.1685976  0.402
2019 Kruglov O, Johnson LD, Uger RA, Wong M, Wu X, Hwang ST, Akilov OE. Anti-CD7 immunotherapy is mediated by cytotoxic CD107a+IFN-γ– NK cells and can be potentiated by interferon-α in cutaneous lymphoma European Journal of Cancer. 119: S33. DOI: 10.1016/s0959-8049(19)30600-8  0.324
2018 Querfeld C, Thompson J, Taylor MH, Pillai R, Johnson LD, Catalano T, Petrova PS, Thompson T, Uger RA, Shou Y, Akilov OE. Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial Blood. 132: 1653-1653. DOI: 10.1182/Blood-2018-99-116915  0.351
2018 Lin GHY, Viller NN, Chabonneau M, Brinen L, Mutukura T, Dodge K, Helke S, Chai V, House V, Lee V, Chen H, O'Connor A, Jin D, Figueredo R, Vareki SM, ... ... Johnson LD, et al. Abstract 2709: TTI-622 (SIRPα-IgG4 Fc), a CD47-blocking innate immune checkpoint inhibitor, suppresses tumor growth and demonstrates enhanced efficacy in combination with antitumor antibodies in both hematologic and solid tumor models Cancer Research. 78: 2709-2709. DOI: 10.1158/1538-7445.Am2018-2709  0.383
2018 Querfeld C, Thompson JA, Taylor M, Pillai R, Johnson LD, Catalano T, Petrova PS, Uger BA, Irwin M, Thompson T, Sievers EL, Akilov O. Intralesional Injection of the CD47-blocking immune checkpoint inhibitor TTI-621 (SIRPaFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and Sézary syndrome: Interim results of a multicenter Phase 1 trial European Journal of Cancer. 101: S34. DOI: 10.1016/J.Ejca.2018.07.297  0.372
2017 Lin GHY, Chai V, Lee V, Dodge K, Truong T, Wong M, Johnson LD, Linderoth E, Pang X, Winston J, Petrova PS, Uger RA, Viller NN. TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets. Plos One. 12: e0187262. PMID 29084248 DOI: 10.1371/Journal.Pone.0187262  0.403
2017 Johnson L, Pillai RK, King RL, Ansell SM, Chen RW, Flinn I, Maris MB, Irwin M, Sievers EL, Petrova PS, Uger RA. Effects of TTI-621 (SIRPαFc) on CD47 and serum cytokines associated with phagocytosis in subjects with relapsed, refractory hematologic malignancies: Pharmacodynamic findings from a first-in-human clinical trial. Journal of Clinical Oncology. 35: 112-112. DOI: 10.1200/Jco.2017.35.7_Suppl.112  0.502
2017 Thompson JA, Akilov O, Querfeld C, Taylor MH, Johnson L, Catalano T, Petrova PS, Uger RA, Irwin M, Sievers EL. A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides. Journal of Clinical Oncology. 35: TPS3101-TPS3101. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps3101  0.444
2017 Querfeld C, Thompson J, Taylor M, Pillai R, Johnson LD, Catalano T, Petrova PS, Uger RA, Irwin M, Sievers EL, Akilov OE. A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 Do Not Eat Signal Blood. 130: 4076-4076. DOI: 10.1182/Blood.V130.Suppl_1.4076.4076  0.416
2017 Linderoth E, Helke S, Lee V, Mutukura T, Wong M, Lin GH, Johnson LD, Pang X, Winston J, Petrova PS, Uger RA, Viller NN. Abstract 2653: The anti-myeloma activity of TTI-621 (SIRPαFc), a CD47-blocking immunotherapeutic, is enhanced when combined with a proteasome inhibitor Cancer Research. 77: 2653-2653. DOI: 10.1158/1538-7445.Am2017-2653  0.468
2017 Lin GH, Charbonneau M, Chai V, O'Connor AM, Bossen B, Chen H, Wong M, Viller NN, Linderoth E, Johnson LD, Pang X, Winston J, Petrova PS, Uger RA. Abstract 2646: Intratumoral delivery of TTI-621 (SIRPαFc), a CD47-blocking immunotherapeutic, inhibits tumor growth and prolongs animal survival in a subcutaneous B cell lymphoma model Cancer Research. 77: 2646-2646. DOI: 10.1158/1538-7445.Am2017-2646  0.408
2016 Petrova PS, Viller NN, Wong M, Pang X, Lin GH, Dodge K, Chai V, Chen H, Lee V, House V, Vigo NT, Jin D, Mutukura T, Charbonneau M, Truong T, ... ... Johnson LD, et al. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Anti-Tumor Activity and Minimal Erythrocyte Binding. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27856600 DOI: 10.1158/1078-0432.Ccr-16-1700  0.478
2016 Ansell S, Chen RW, Flinn IW, Maris MB, O'Connor OA, Johnson LD, Irwin M, Petrova PS, Uger RA, Sievers EL. A Phase 1 Study of TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies Blood. 128: 1812-1812. DOI: 10.1182/Blood.V128.22.1812.1812  0.394
2016 Viller NN, Truong T, Linderoth E, Johnson LD, Viau S, Lin GHY, Wong M, Pang X, Petrova PS, Uger RA. Abstract B028: Blockade of the CD47 “Do not eat” signal by TTI-621 (SIRPαFc) leads to enhanced antitumor CD8+ T cell responses in vitro Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B028  0.555
2013 Johnson LD, Beckham WA, Russell GH, Lum JJ, Vlachaki MT. Abstract B51: Synergistic effects of αCTLA-4 and radiotherapy in the treatment of prostate cancer. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-B51  0.378
2012 Johnson LD, Jameson SC. TGF-β sensitivity restrains CD8+ T cell homeostatic proliferation by enforcing sensitivity to IL-7 and IL-15. Plos One. 7: e42268. PMID 22879925 DOI: 10.1371/Journal.Pone.0042268  0.61
2010 Johnson LD, Jameson SC. Self-specific CD8+ T cells maintain a semi-naive state following lymphopenia-induced proliferation. Journal of Immunology (Baltimore, Md. : 1950). 184: 5604-11. PMID 20393139 DOI: 10.4049/Jimmunol.1000109  0.646
2009 Johnson LD, Jameson SC. Immunology. A chronic need for IL-21. Science (New York, N.Y.). 324: 1525-6. PMID 19541985 DOI: 10.1126/Science.1176487  0.596
2009 Haluszczak C, Akue AD, Hamilton SE, Johnson LD, Pujanauski L, Teodorovic L, Jameson SC, Kedl RM. The antigen-specific CD8+ T cell repertoire in unimmunized mice includes memory phenotype cells bearing markers of homeostatic expansion. The Journal of Experimental Medicine. 206: 435-48. PMID 19188498 DOI: 10.1084/Jem.20081829  0.595
Show low-probability matches.